Zacks Industry Outlook Highlights: Johnson & Johnson, Hologic, Abbott Laboratories, AbbVie and Quest Diagnostics

    Zacks Industry Outlook Highlights: Johnson & Johnson, Hologic, Abbott
                  Laboratories, AbbVie and Quest Diagnostics

PR Newswire

CHICAGO, Jan. 30, 2013

CHICAGO, Jan. 30, 2013 /PRNewswire/ --Today, Zacks Equity Research discusses
the U.S. Medical Technology, including Johnson & Johnson (NYSE:JNJ), Hologic
(Nasdaq:HOLX), Abbott Laboratories (NYSE:ABT), AbbVie (NYSE:ABBV) and Quest
Diagnostics (NYSE:DGX).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

A synopsis of today's Industry Outlook is presented below. The full article
can be read at 

Link: 
http://www.zacks.com/commentary/25607/medtech-industry-stock-outlook-jan-2013

We are in the midst of the fourth quarter earnings season and it is once again
time to review the players in the worldwide medical devices market. The US
still holds the leading position with almost one-third of the market share.
However, emerging economies like Brazil, Russia, India and China –
collectively known as the BRICs – are fast coming up in the medical devices
space and are attracting a lot of attention.

These emerging economies are seeing an increasing uptake of medical devices
due largely to growing medical awareness and economic prosperity. Expansion
in emerging markets, especially those with double-digit annual growth rates,
represents one of the best potential avenues for growth in 2013 and beyond.

On the flip side, the MedTech industry is currently plagued by several issues
including the 2.3% medical device excise tax, pricing concerns, hospital
admission and procedural volume pressures, Medicare reimbursement issues and
regulatory overhang. Percutaneous intervention (angioplasty) volumes continue
to be relatively flat in the US, Japan and Europe, with improvement not
expected anytime soon.

In spite of several uncertainties resulting in constrained capital spending,
the past year also witnessed significant M&A deals including acquisitions of
Switzerland-based Synthes Inc. by Johnson & Johnson (NYSE:JNJ) for a whopping
$19.7 billion, Gen-Probe Inc. by Hologic (Nasdaq:HOLX) for $3.8 billion
andothers.

Another trend that we have been observing of late is the divestment of
non-core business segments. For example, in early January, Abbott Laboratories
(NYSE:ABT) separated its research-based pharmaceuticals business by creating a
new company, AbbVie (NYSE:ABBV), to allow the two separate entities to perform
in a more focused manner.

In January, diagnostic testing company Quest Diagnostics (NYSE:DGX) divested
its OralDNA Labs salivary-diagnostics business to Access Genetics. The sale of
the company's HemoCue diagnostic products business is also in the works. This
would enable the company to refocus its attention on its core diagnostic
information services. Moreover, Johnson & Johnson is currently looking for
opportunities to sell or spin off its Ortho Clinical Diagnostics business.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at
http://at.zacks.com/?id=4581.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.